Communication

News

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre

18 October 2021
News

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre

October 07, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA’s subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector. To know more